Invitae reported $66.3 million in revenues for the fourth quarter, which fell short of the consensus Wall Street estimate of $68.1 million.
Paired tumor/germline analysis is not routinely done in cancer care, but some labs are starting to report incidental germline findings alongside patient's tumor profiles.
Of the 28 companies in the index, 16 companies' share prices increased while the share values of 12 declined month over month.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
Invitae estimated that in 2020 it would accession more than 725,000 samples and bring in more than $330 million in revenue, slightly above current Wall Street projections.
Of the 39 deals included in the analysis, only three exceeded $100 million in value, with the rest having significantly smaller price tags or prices that were not disclosed.
In seven years, the public variant classification database has steadily become a resource that labs are submitting to and that genetics experts are consulting.
Amid rapid adoption of multi-gene panels, ACMG experts are seeing some doctors and patients taking actions they shouldn't.
Invitae will provide genetic testing for 109 genes associated with the conditions, while BioMarin will provide financial support for the program.
Of the 28 companies in the index, 21 companies' share prices increased while the share values of 7 declined month over month.